title: Mechanism of action of immunomodulatory agents in multiple myeloma.
abstract: Immunomodulatory agents (IMiD's) have become an important drug category in the treatment of multiple myeloma. The agents have a complex mechanism of action that influence the microenvironment in the bone marrow. The microenvironment is an essential promotor of disease progression and therefore important in targeting the disease. The article reviews mechanism of action and essential pathways of IMiD's that are important in disease treatment.
authors.affiliation: VA Boston Healthcare System, Boston, MA, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reske
authors.forename: Mariateresa
authors.initials: M
authors.lastname: Fulciniti
authors.forename: Nikhil C
authors.initials: NC
authors.lastname: Munshi
mesh_terms: D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D013792:Thalidomide
references.citation: Ther Clin Risk Manag. 2008 Feb;4(1):129-36
references.pmid: 18728702
references.citation: Blood. 2004 Mar 1;103(5):1787-90
references.pmid: 14512311
references.citation: Cancer Res. 2002 Apr 15;62(8):2300-5
references.pmid: 11956087
references.citation: Oncogene. 2003 Apr 24;22(16):2417-21
references.pmid: 12717418
references.citation: Blood. 1996 Feb 1;87(3):1104-12
references.pmid: 8562936
references.citation: Hematol Oncol Clin North Am. 1997 Feb;11(1):27-42
references.pmid: 9081202
references.citation: J Biol Chem. 2002 May 10;277(19):16639-47
references.pmid: 11872748
references.citation: Blood. 2002 Jun 15;99(12):4525-30
references.pmid: 12036884
references.citation: Clin Cancer Res. 2006 Dec 1;12(23):7165-73
references.pmid: 17145842
references.citation: Cancer Res. 2005 Dec 15;65(24):11712-20
references.pmid: 16357183
references.citation: J Bone Miner Metab. 2009;27(1):16-23
references.pmid: 19057841
references.citation: Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8
references.pmid: 16344099
references.citation: Nat Rev Cancer. 2002 Dec;2(12):927-37
references.pmid: 12459731
references.citation: Blood. 2003 Aug 15;102(4):1435-42
references.pmid: 12714512
references.citation: Leukemia. 2007 Sep;21(9):1875-84
references.pmid: 17611556
references.citation: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
references.pmid: 7513432
references.citation: Leuk Lymphoma. 2008 Jul;49(7):1238-45
references.pmid: 18452080
references.citation: Br J Cancer. 2002 Nov 4;87(10):1166-72
references.pmid: 12402158
references.citation: Blood. 1999 May 1;93(9):3044-52
references.pmid: 10216101
references.citation: Leukemia. 2001 Dec;15(12):1950-61
references.pmid: 11753617
references.citation: Blood. 2004 Dec 15;104(13):4188-93
references.pmid: 15319277
references.citation: Drug Discov Today. 2005 Jan 15;10(2):107-14
references.pmid: 15718159
references.citation: J Immunol. 1997 Jul 1;159(1):487-96
references.pmid: 9200490
references.citation: Oncogene. 2001 Sep 20;20(42):5991-6000
references.pmid: 11593406
references.citation: Apoptosis. 2001 Feb-Apr;6(1-2):47-55
references.pmid: 11321040
references.citation: Exp Eye Res. 1997 Jun;64(6):971-8
references.pmid: 9301478
references.citation: J Cell Biochem. 2007 Jul 1;101(4):950-68
references.pmid: 17546631
references.citation: Br J Haematol. 2007 May;137(3):268-9
references.pmid: 17408469
references.citation: Leukemia. 2008 Oct;22(10):1925-32
references.pmid: 18596740
references.citation: Lancet. 2006 Mar 11;367(9513):825-31
references.pmid: 16530576
references.citation: Hematol Oncol Clin North Am. 2007 Dec;21(6):1071-91, viii-ix
references.pmid: 17996589
references.citation: Blood. 2002 Nov 1;100(9):3063-7
references.pmid: 12384400
references.citation: Mol Med. 1996 Jul;2(4):506-15
references.pmid: 8827720
references.citation: Blood. 2001 Jul 1;98(1):210-6
references.pmid: 11418482
references.citation: Leukemia. 2009 Dec;23(12):2222-32
references.pmid: 19741729
references.citation: Blood. 1999 Mar 1;93(5):1658-67
references.pmid: 10029595
references.citation: J Immunol. 1999 Jul 1;163(1):380-6
references.pmid: 10384139
references.citation: Eur J Biochem. 1998 Jun 15;254(3):439-59
references.pmid: 9688254
references.citation: N Engl J Med. 1999 Nov 18;341(21):1565-71
references.pmid: 10564685
references.citation: Leuk Res. 2006 Jul;30(7):849-58
references.pmid: 16494942
references.citation: J Clin Oncol. 2007 Oct 1;25(28):4459-65
references.pmid: 17785703
references.citation: Blood. 2002 Mar 15;99(6):2162-71
references.pmid: 11877293
references.citation: Blood. 2007 Jul 1;110(1):334-8
references.pmid: 17371942
references.citation: Blood. 2000 Nov 1;96(9):2943-50
references.pmid: 11049970